Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Short Interest Down 26.5% in March

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) was the target of a significant decline in short interest during the month of March. As of March 31st, there was short interest totaling 196,901 shares, a decline of 26.5% from the March 15th total of 267,884 shares. Approximately 5.9% of the company’s shares are short sold. Based on an average daily trading volume, of 41,997 shares, the short-interest ratio is currently 4.7 days.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. HC Wainwright lowered Ekso Bionics from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ekso Bionics in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Ekso Bionics currently has a consensus rating of “Reduce” and an average target price of $6.00.

Insider Buying and Selling at Ekso Bionics

In other news, major shareholder Daniel Asher acquired 15,540 shares of the business’s stock in a transaction dated Thursday, February 19th. The stock was acquired at an average price of $12.30 per share, with a total value of $191,142.00. Following the completion of the transaction, the insider directly owned 270,432 shares in the company, valued at approximately $3,326,313.60. This represents a 6.10% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Ekso Bionics

Several institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new stake in shares of Ekso Bionics during the 3rd quarter valued at $57,000. Shay Capital LLC purchased a new stake in shares of Ekso Bionics during the 3rd quarter valued at $67,000. Citadel Advisors LLC acquired a new position in Ekso Bionics in the third quarter valued at $198,000. Geode Capital Management LLC boosted its holdings in Ekso Bionics by 68.9% in the fourth quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock valued at $218,000 after acquiring an additional 10,281 shares during the last quarter. Finally, Consolidated Portfolio Review Corp acquired a new position in Ekso Bionics in the third quarter valued at $333,000. 6.42% of the stock is owned by hedge funds and other institutional investors.

Ekso Bionics Trading Up 2.6%

Shares of EKSO traded up $0.26 during mid-day trading on Wednesday, hitting $10.26. The company had a trading volume of 30,337 shares, compared to its average volume of 181,883. Ekso Bionics has a 1-year low of $2.73 and a 1-year high of $13.50. The business’s 50-day simple moving average is $10.41 and its 200-day simple moving average is $7.50. The stock has a market cap of $36.53 million, a PE ratio of -2.00 and a beta of 0.77. The company has a quick ratio of 1.07, a current ratio of 1.63 and a debt-to-equity ratio of 0.09.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.